Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Management Strategies for Pyoderma Gangrenosum: An Interdisciplinary Approach
Description
This case presentation discusses a 34-year-old male patient with a history of ulcerative colitis and autoimmune liver disease, presenting with possible pyoderma gangrenosum (PG) that did not improve with standard treatments. Initially, the patient was on infliximab and azathioprine, along with prednisone. However, his ulcers persisted, leading to further investigation. A biopsy confirmed neutrophil presence but revealed inadequate infliximab levels and high levels of anti-drug antibodies. The treatment strategy was adjusted to prioritize immediate inflammation control and optimize wound healing. Corticosteroids and cyclosporine were considered, and after consultation with gastroenterology, the patient was switched to intravenous cyclosporine along with continued prednisone. Therapeutic drug monitoring was emphasized to ensure effective medication levels and prevent complications linked with anti-drug antibodies. Ultimately, the treatment regimen was tailored based on the patient's response and comorbidities, resulting in a significant improvement and successful management of PG.
View moreConclusions
- High-dose immunosuppression is ineffective for treating venous stasis ulcers that may mimic pyoderma gangrenosum (PG).
- Immediate control of inflammation is crucial for managing PG, requiring fast-acting immunosuppressive agents like corticosteroids and possibly cyclosporine.
- Monitoring infliximab trough levels can guide treatment decisions and optimize patient outcomes, particularly in complex cases like PG with underlying conditions.
- Long-term management for PG may involve biologic therapy such as anti-IL-12/23 agents or Jak inhibitors alongside proper wound care.
- When patients do not respond to a biologic, measuring drug levels can indicate whether to switch classes or escalate doses within the same class of medication.
- Serious adverse reactions occur more frequently with prednisolone compared to cyclosporine in treating PG.
- Therapeutic drug monitoring can inform adjustments and avoid unnecessary treatment delays while ensuring optimal therapeutic drug levels.
- Nat Rev Dis Primers. 2020 Oct 8;6(1):81
- Ormerad et al BMJ. 2015 Jun 12:350:h2958
- Alavi A. Journal of Investigative Dermatology (2023) 143, 1625e1628